Bosentan and Pulmonary Endothelial Function

Summary

6 months therapy of Bosentan, an endothelin antagonist, will lead to improvement in pulmonary microvascular endothelial function.

Timeline

Start

2006-04

Primary completion

2009-05

Completion

2009-12

Drugs

Indications